Analog chipmaker TI expects free cash flow to jump in 2026 By Reuters
(Reuters) – Texas Instruments (NASDAQ:) said on Tuesday its free cash flow (FCF) would jump in 2026 as demand rebounds and the analog chipmaker tightens capital spending after pressure from activist investor Elliott Investment Management.
It expects FCF per share to be between $8 and $12 in 2026, higher than an estimate of $6.91, according to eight analysts polled by Visible Alpha.
Elliott, which in May disclosed a $2.5 billion stake, had pushed the chipmaker to tighten spending and adjust its production capacity to the changes in demand. It had said the strategy could improve TI’s FCF to $9 per share by 2026.
The company has embarked on an aggressive plan to bring more production in house with the construction of three new chip facilities. It has also seen signs of an uptick in demand in recent months after a prolonged slump.
TI said it expects capital expenditure in 2026 to be between $2 billion and $5 billion, compared with its initial plans to spend about $5 billion a year through 2026 to expand manufacturing.
The company will maintain capital expenditure of $5 billion through 2025. Its free cash flow per share fell 77% to $1.47 in 2023, according to LSEG data.
It expects revenue to be between $20 billion to $26 billion for 2026.
You Might Also Like
Sempra Energy stock hits 52-week high at $84.28 amid robust growth By Investing.com
Sempra Energy (NYSE:) stock has reached a new 52-week high, touching $84.28, as the company continues to exhibit strong performance....
No change to US policy on long-range missiles to Ukraine expected Friday, White House says By Reuters
By Doina Chiacu WASHINGTON (Reuters) - The United States is not planning to announce any new policy on Ukraine and...
Morgan Stanley expects mergers, IPOs to lag trends through 2024 By Reuters
By Tatiana Bautzer and Arasu Kannagi Basil NEW YORK (Reuters) -Morgan Stanley expects activity for mergers, acquisitions and initial public...
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients12...